← Browse by Condition

Medical Condition

diffuse large b cell lymphoma

Total Trials

16

Recruiting Now

16

Trial Phases

Phase 3, Phase 1, Phase 1, Phase 2

Lymphoma trials span diffuse large B-cell lymphoma (DLBCL), follicular lymphoma, Hodgkin lymphoma, mantle cell lymphoma, and T-cell lymphomas β€” each with distinct biology and treatment response. CAR-T cell therapy has established a new standard in relapsed/refractory DLBCL, and trials now aim to move this approach earlier in the treatment sequence.

Active trials evaluate bispecific antibodies (mosunetuzumab, epcoritamab, glofitamab), next-generation CAR-T cell products (CD19/CD22 dual targets, BCMA-targeting), BTK inhibitors in B-cell lymphomas, and total metabolic volume on PET as a predictive biomarker for treatment adaptation.

Frequently Asked Questions — diffuse large b cell lymphoma Clinical Trials

How many clinical trials are currently recruiting for diffuse large b cell lymphoma?

ClinicalMetric currently tracks 16 actively recruiting clinical trials for diffuse large b cell lymphoma, sourced in real time from ClinicalTrials.gov. The total number of registered studies—including those not yet enrolling or in active follow-up—is 16. Trial availability changes daily as new studies open enrollment and existing ones reach capacity.

What trial phases are available for diffuse large b cell lymphoma?

diffuse large b cell lymphoma research spans Phase 1 (9 trials), Phase 2 (6 trials), Phase 3 (1 trial). Phase 1 studies evaluate safety and dosing in small groups, Phase 2 studies assess preliminary efficacy in 100–300 participants, and Phase 3 trials compare the new treatment against the standard of care in 300–3,000+ patients. Phase 4 post-approval studies monitor long-term outcomes in real-world populations.

How do I find out if I qualify for a diffuse large b cell lymphoma clinical trial?

Eligibility criteria for diffuse large b cell lymphoma trials vary by study and typically specify age range, disease stage or severity, prior treatment history, and specific diagnostic or laboratory parameters. Each listing on ClinicalMetric links to the full protocol on ClinicalTrials.gov, where inclusion and exclusion criteria are documented. Contact the sponsoring site's research coordinator directly to confirm your eligibility—your treating physician or specialist can also help identify the most appropriate trial based on your medical history and current treatment status.

Trial Phases

Phase 1

9

Phase 2

6

Phase 3

1

Top Sponsors

Novartis Pharmaceuticals 2 trials

Suzhou Suncadia Biopharmaceuticals Co., Ltd. 1 trial

Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS 1 trial

City of Hope Medical Center 1 trial

Jonsson Comprehensive Cancer Center 1 trial

Recruiting Clinical Trials

NCT06929624 Phase 3

A Phase 3 Clinical Study of SHR-A1912 Combined With R-GemOx Versus R-GemOx in Diffuse Large B-cell Lymphoma

Suzhou Suncadia Biopharmaceuti...

Mixed Molecular Clinical Index (MMCI) in Diffuse Large B-cell Lymphoma (DLBCL)

Istituto Romagnolo per lo Stud...

NCT05432635 Phase 1

Genetically Modified T-cells (CMV-Specific CD19-CAR T-cells) Plus a Vaccine (CMV-MVA Triplex) Following Stem Cell Transplantation for the Treatment of Intermediate or High Grade B-cell Non-Hodgkin Lymphoma

City of Hope Medical Center

NCT05256641 Phase 1, Phase 2

Acalabrutinib Maintenance for the Treatment of Patients With Large B-cell Lymphoma

Jonsson Comprehensive Cancer C...

NCT04775745 Phase 1

Study of Oral Administration of LP-168 in Patients With Relapsed or Refractory B-cell Malignancies.

Newave Pharmaceutical Inc

NCT06651853 Phase 2

Large Fraction Radiation Therapy Combined With Lenalidomide, and Glofitamab in Refractory Relapsed DLBCL

The First Affiliated Hospital ...

NCT04512716 EARLY_Phase 1

Iomab-ACT: A Pilot Study of 131-I Apamistamab Followed by CD19-Targeted CAR T-Cell Therapy for Patients With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia or Diffuse Large B-Cell Lymphoma

Memorial Sloan Kettering Cance...

NCT05006716 Phase 1, Phase 2

A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies

United States, Austr...

BeOne Medicines

NCT04104776 Phase 1, Phase 2

A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas

United States, Franc...

Novartis Pharmaceuticals

NCT06244368 Phase 2

GVM±R in Patients With Relapsed or Refractory Aggressive NHL.

Institute of Hematology & Bloo...

A Study of Ultra-fraction Radiotherapy Bridging CART in R/R DLBCL

Peking Union Medical College H...

NCT05365659 Phase 1

IKS03 in Patients With Advanced B Cell Non-Hodgkin Lymphomas

United States, Austr...

Iksuda Therapeutics Ltd.

NCT06120166 EARLY_Phase 1

Safety and Efficacy of Metabolically Armed CD19 CAR-T Cells (Meta10-19) in the Treatment of r/r DLBCL Clinical Research

Effectiveness and Safety of Tisagenlecleucel Therapy in Brazilian Patients With B-lymphocyte Malignancies

Novartis Pharmaceuticals

Metabolic and Immunomic Differential Analysis of Primary Central Nervous System Diffuse Large B-Cell Lymphoma

NCT06395103 Phase 1, Phase 2

Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)

United States, Austr...

Merck Sharp & Dohme LLC

Related Conditions

mantle cell lymphoma (4) follicular lymphoma (4) b cell non hodgkin lymphoma (2) marginal zone lymphoma (2) b all (2) recurrent b cell non hodgkin lymphoma (1) recurrent diffuse large b cell lymphoma (1) recurrent mantle cell lymphoma (1) recurrent transformed non hodgkin lymphoma (1) transformed non hodgkin lymphoma (1) high grade b cell lymphoma (1) transformed lymphoma (1)

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer · Last Reviewed: September 2026 · Data Methodology